Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD

Video

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

Related Videos
Kasperi Kankare at the iCare booth at ESCRS
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, speaking at ASRS 2023.
Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, at ASRS 2023.
Baruch Kupperman, MD, PhD, speaks with David Hutton of Ophthalmology Times.
Related Content
© 2023 MJH Life Sciences

All rights reserved.